Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors

被引:27
作者
Chou, FP
Chu, SC
Cheng, MC
Yang, SF
Cheung, WN
Chiou, HL
Hsieh, YS [1 ]
机构
[1] Chung Shan Med Univ, Inst Biochem, Taichung 402, Taiwan
[2] Chung Shan Med Univ, Sch Med, Taichung 402, Taiwan
[3] Gods Help Hosp, Nephrol & Dialysis Unit, Tai Pauo City, Chia Yi, Taiwan
[4] Chungtai Inst Hlth Sci & Technol, Dept Food Sci, Taichung 406, Taiwan
关键词
hemodialysis; MMP-2; MMP-9; TIMP-1; TIMP-2;
D O I
10.1016/S0009-9120(02)00331-4
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Increased cell expression of matrix metalloproteinase-9 (MMP-9) was associated with the development of atherosclerosis and osseoarticular tissue destruction in hemodialysis patients. In this study, the pre- and post-HD plasma concentrations of type IV collagenases and their inhibitors in HD patients were examined. Design and methods: Commercial ELISA kits and Zymography techniques were used to assay the parameters in 40 patients pre- and post-HD session. Results: After the hemodialysis process, MMP-9, MMP-2 and TIMP-2 levels Were 124 +/- 72, 706 +/- 242 and 248 +/- 90 ng/mL, significantly different from the pre-HD values (187 +/- 149, 759 +/- 304 and 4 +/- 14 ng/mL). TIMP-1 were not affected by HD. Female subjects and patients with chronic glomerulonephritis had higher TIMP-2 than their counterparts (p < 0.05). The effect of gender on MMP-2 levels. was interacted with that of membrane types (p < 0.01). Conclusion: These results indicated that the hemodialysis process tends to decrease the overall activity of the peripheral plasma MMP system in HD patients. (C) 2002 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:383 / 388
页数:6
相关论文
共 26 条
[1]  
Alexander CM, 1991, CELL BIOL EXTRACELLU, P255
[2]   Oxidative damage during hemodialysis using a vitamin-E-modified dialysis membrane: A preliminary characterization [J].
Buoncristiani, U ;
Galli, F ;
Rovidati, S ;
Albertini, MC ;
Campus, G ;
Canestrari, F .
NEPHRON, 1997, 77 (01) :57-61
[3]   Matrix metalloproteinases and coronary artery disease: A novel therapeutic target [J].
Celentano, DC ;
Frishman, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (11) :991-1000
[4]   Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome [J].
Créange, A ;
Sharshar, T ;
Planchenault, T ;
Christov, C ;
Poron, F ;
Raphaël, JC ;
Gherardi, RK .
NEUROLOGY, 1999, 53 (08) :1683-1691
[5]   Influence of dialysis on plasma lipid peroxidation products and antioxidant levels [J].
Daschner, M ;
Lenhartz, H ;
Botticher, D ;
Schaefer, F ;
Wollschlager, M ;
Mehls, O ;
Leichsenring, M .
KIDNEY INTERNATIONAL, 1996, 50 (04) :1268-1272
[6]   Metalloproteinase-9 mRNA expression in monocytes from patients with chronic renal failure [J].
Ebihara, I ;
Nakamura, T ;
Tomino, Y ;
Shimada, N ;
Koide, H .
AMERICAN JOURNAL OF NEPHROLOGY, 1998, 18 (04) :305-310
[7]   Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus [J].
Ebihara, I ;
Nakamura, T ;
Shimada, N ;
Koide, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (04) :544-550
[8]  
Endo K, 1997, ANTICANCER RES, V17, P2253
[9]  
Garzetti GG, 1996, ANTICANCER RES, V16, P2123
[10]  
Goetzl EJ, 1996, J IMMUNOL, V156, P1